Abstract
Background: As one of the most common cancers globally, hepatocellular carcinoma (HCC) usually has a poor prognosis. Many HCC patients are usually diagnosed at advanced stages. Therefore, new potential biomarkers for the diagnosis and prognosis of HCC are urgently needed. More and more studies have shown that miR-92a-3p can regulate the occurrence and development of various cancers, but its clinical significance and molecular mechanism in HCC are still elusive. Here, we tried to clarify the regulatory mechanism of miR-92a-3p in HCC.
Methods: In this study, we conducted qRT-PCR and revealed that miR-92a-3p was notably upregulated in HCC cells. MTT, flow cytometry, wound healing, Transwell invasion assays and western blot were conducted to uncover that overexpressed miR-92a-3p could boost the proliferation, migration, invasion and epithelial-mesenchymal transition (EMT) of HCC cells while inhibiting cell apoptosis. In addition, the proteins associated with the PI3K/AKT/mTOR pathway were also detected by western blot.
Results: It was suggested that miR-92a-3p could activate the PI3K/AKT/mTOR signaling pathway.
Conclusion: These results suggest that miR-92a-3p plays a tumor-promoting role in HCC and may be a potential biomarker for the diagnosis and prognosis of HCC.
Keywords: Hepatocellular carcinoma (HCC), miR-92a-3p, PI3K/AKT/mTOR signaling pathway, epithelial-mesenchymal transition (EMT), MTT, MiRNAs.
Current Pharmaceutical Design
Title:MiR-92a-3p Promotes the Malignant Progression of Hepatocellular Carcinoma by Mediating the PI3K/AKT/mTOR Signaling Pathway
Volume: 27 Issue: 29
Author(s): Libing Wang, Mingxin Cui, Fengzhi Qu, Daming Cheng, Jingkun Yu, Zhaoyuan Tang, Ling Cheng, Yanbing Wei, Xiaotang Wu and Xiaogang Liu*
Affiliation:
- Department of Hepatobiliary Surgery, Tangshan Gongren Hospital, Tangshan, 063000,China
Keywords: Hepatocellular carcinoma (HCC), miR-92a-3p, PI3K/AKT/mTOR signaling pathway, epithelial-mesenchymal transition (EMT), MTT, MiRNAs.
Abstract:
Background: As one of the most common cancers globally, hepatocellular carcinoma (HCC) usually has a poor prognosis. Many HCC patients are usually diagnosed at advanced stages. Therefore, new potential biomarkers for the diagnosis and prognosis of HCC are urgently needed. More and more studies have shown that miR-92a-3p can regulate the occurrence and development of various cancers, but its clinical significance and molecular mechanism in HCC are still elusive. Here, we tried to clarify the regulatory mechanism of miR-92a-3p in HCC.
Methods: In this study, we conducted qRT-PCR and revealed that miR-92a-3p was notably upregulated in HCC cells. MTT, flow cytometry, wound healing, Transwell invasion assays and western blot were conducted to uncover that overexpressed miR-92a-3p could boost the proliferation, migration, invasion and epithelial-mesenchymal transition (EMT) of HCC cells while inhibiting cell apoptosis. In addition, the proteins associated with the PI3K/AKT/mTOR pathway were also detected by western blot.
Results: It was suggested that miR-92a-3p could activate the PI3K/AKT/mTOR signaling pathway.
Conclusion: These results suggest that miR-92a-3p plays a tumor-promoting role in HCC and may be a potential biomarker for the diagnosis and prognosis of HCC.
Export Options
About this article
Cite this article as:
Wang Libing , Cui Mingxin , Qu Fengzhi , Cheng Daming , Yu Jingkun, Tang Zhaoyuan , Cheng Ling , Wei Yanbing, Wu Xiaotang and Liu Xiaogang *, MiR-92a-3p Promotes the Malignant Progression of Hepatocellular Carcinoma by Mediating the PI3K/AKT/mTOR Signaling Pathway, Current Pharmaceutical Design 2021; 27 (29) . https://dx.doi.org/10.2174/1381612827666210612054156
DOI https://dx.doi.org/10.2174/1381612827666210612054156 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Peroxisome Proliferator-Activated Receptors: Role of Isoform Gamma in the Antineoplastic Effect of Iodine in Mammary Cancer
Current Cancer Drug Targets Wnt/beta-Catenin Signaling and Small Molecule Inhibitors
Current Pharmaceutical Design Folate Targeted Solid Lipid Nanoparticles of Simvastatin for Enhanced Cytotoxic Effects of Doxorubicin in Chronic Myeloid Leukemia
Current Nanoscience Mode of Action of Long-Term Low-Dose Macrolide Therapy for Chronic Sinusitis in the Light of Neutrophil Recruitment
Current Drug Targets - Inflammation & Allergy Genistein Potentiates the Anti-cancer Effects of Gemcitabine in Human Osteosarcoma via the Downregulation of Akt and Nuclear Factor-κB Pathway
Anti-Cancer Agents in Medicinal Chemistry Anti-cancer and Anti-angiogenic Properties of Various Natural Pentacyclic Tri-terpenoids and Some of their Chemical Derivatives
Current Organic Chemistry Insight to Physiology and Pathology of Zinc(II) Ions and Their Actions in Breast and Prostate Carcinoma
Current Medicinal Chemistry Therapeutic Use of MicroRNAs in Cancer
Anti-Cancer Agents in Medicinal Chemistry Clinical Trials with Intracerebral Convection-Enhanced Delivery of Targeted Toxins in Malignant Glioma
Reviews on Recent Clinical Trials The Immunoregulatory Protein Human B7H3 is a Tumor-Associated Antigen that Regulates Tumor Cell Migration and Invasion
Current Cancer Drug Targets Hypericin - A New Antiviral and Antitumor Photosensitizer: Mechanism of Action and Interaction with Biological Macromolecules
Current Drug Targets Current Status of Delivery Systems to Improve Target Efficacy of Oligonu-cleotides
Current Pharmaceutical Design Nutritional Attributes and Health Application of Seabuckthorn (<i>Hippophae rhamnoides</i> L.) – A Review
Current Nutrition & Food Science Erythrocyte-cancer Hybrid Membrane-camouflaged Mesoporous Silica Nanoparticles Loaded with Gboxin for Glioma-targeting Therapy
Current Pharmaceutical Biotechnology Ovarian Cancer - Angiogenesis and Targeted Therapy
Current Angiogenesis (Discontinued) Specific Targeted Therapy: A New Tool for the Destruction of Cancer
Current Drug Therapy Delineation of Current Development of Antimitotic Compounds Targeting Cytoskeletal Protein Tubulin and Microtubule in the Cancer Therapy
Current Chemical Biology Multidrug Transporters as Drug Targets
Current Drug Targets Integrative Neurochemistry and Neurobiology of Social Recognition and Behavior Analyzed with Respect to CD38-Dependent Brain Oxytocin Secretion
Current Topics in Medicinal Chemistry Emerging Strategies to Strengthen the Anti-Tumour Activity of Type I Interferons: Overcoming Survival Pathways
Current Cancer Drug Targets